The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has been considered responsible for the prolonged continuation of the coronavirus disease 2019 (COVID-19) pandemic. The fast dissemination of these variants presents a challenge for current vaccines. Next-generation vaccinations must be manufactured and distributed quickly to stop the pandemic. To combat existing variations and stop the development of new ones, coordinated surveillance, the designing of new vaccines, and broad-scale immunization are required. Clinical trials are still being conducted to assess the efficacy of the vaccination against various SARS-CoV-2 variants.